Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
WW announced on Thursday that it will be laying off employees and cutting costs to the tune of $100 million per year.
Novo Nordisk scored approval to sell its Wegovy weight loss drug in China. That’s a big win, but competitors will soon flood in.
A loophole lets the company create a back-door offering of a generic drug before the patents of Novo Nordisk and Eli Lilly expire.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.
A new survey finds evidence that “the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants.”
A GLP-1 medication from French drugmaker Sanofi — similar to Ozempic — was found to slow Parkinson’s in a small mid-stage trial.
Facebook and other social media platforms are the subject of a probe by federal prosecutors into available medications.
The company, now one of Europe’s biggest, is trying to keep supply up with still-astronomical demand.
After a solid 2023, shares of WW International just experienced their worst month ever, falling nearly 60% amid signs of waning demand.
The tight supply of both beans meant trading prices were extremely volatile, and the result was that cocoa almost tripled in price last year.
A portfolio doesn’t have to be just stocks and bonds. You can add something a little more fun, say your favorite vintage baseball cards.
Which way Trump will lean on the issue is difficult to say, though tech companies have worked hard to curry the incoming president’s favor.